The rate-adaptive pacing algorithm space is highly concentrated, with Cardiac Pacemakers Inc commanding a dominant position among the top filers. Annual filing volume peaked in 2020 and has since eased, signaling a maturing field where incremental differentiation and adjacent technology moves now define the competitive frontier.
Cardiac Pacemakers Inc holds the top-ranked position with 127 patent records, more than double the second-ranked Medtronic Inc at 48 patent records — a gap that signals sustained, deliberate portfolio building rather than opportunistic filing.
The top five filers collectively account for 64% of the hundred largest filers' combined total, placing this field in the high-concentration tier. The tier gap between the leader and challengers is wide enough that no single entrant is close to closing the distance in the near term.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Cardiac Pacemakers Inc | 127 | |
| 2 | Medtronic Inc | 48 | |
| 3 | BIOTRONIK SE & CO KG | 28 | |
| 4 | Pacesetter Inc | 22 | |
| 5 | Nevro Corp | 19 | |
| 6 | Intermedics Inc | 10 | |
| 7 | ELA Medical SA | 8 | |
| 8 | Purdue Research Foundation | 7 | |
| 9 | St. Jude Medical AB | 7 | |
| 10 | Alt Eckhard Dr | 6 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | Abiomed Inc | 6 | |
| 12 | Baropace Inc | 6 | |
| 13 | Pastore Joseph M | 5 | |
| 14 | Boston Scientific Neuromodulation Corp | 4 | |
| 15 | Spinelli Julio C | 3 | |
| 16 | Baynham Tamara Colette | 3 | |
| 17 | Arcot Krishnamurthy Shantha | 3 | |
| 18 | Advanced Medical Devices | 3 | |
| 19 | Salo Rodney W | 3 | |
| 20 | Kramer Andrew P | 3 |
The leaders' entrenched positions imply that foundational algorithmic patents are largely occupied; new entrants and smaller challengers must navigate around a dense core and are more likely to find traction in adjacent sensing, data-processing, or power-management branches.
Filing counts for the most recent 18–24 months should be read with caution, as publication lag typically causes those periods to appear under-counted relative to their eventual totals. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Annual filing activity and IPC class distribution together reveal a field that spiked in 2020 and has since settled, while the technology mix shows a dominant electrotherapy core flanked by several smaller, potentially differentiating branches.
Filings rose sharply to a peak in 2020, then retreated; the 2023–2026 window shows very low counts, but this partly reflects normal publication lag for recently filed applications and should not be read as a definitive end to activity.
↗ Hover for values · click a bar to ask EurekaThe A61N electrotherapy class overwhelmingly dominates the IPC mix, confirming that core stimulation-algorithm claims anchor the corpus; A61B diagnosis and surgery, G06F digital data processing, and G16H healthcare informatics form a secondary tier that points to emerging software and sensing dimensions.
↗ Hover for values · click a bar to ask EurekaCitation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
An implantable cardiac pacemaker is adapted to be selectively non-invasively upgraded from time to time after implantation to provide a plurality of different diagnostic, functional, and pacing operational modes in the form of respective combinations of single and dual chamber sensing and pacing and rate-adaptive pacing of a patient's heart to correct any… (excerpt from the patent abstract)
Open this patent in Eureka →| # | Patent | Citations |
|---|---|---|
| 1 | Implantable stimulation device having means for op… | 654 |
| 2 | Programmable multi-mode cardiac pacemaker | 630 |
| 3 | Dual indifferent electrode pacemaker | 607 |
| 4 | Microprocessor controlled rate-responsive pacemake… | 547 |
| 5 | Vagal nerve stimulation techniques for treatment o… | 519 |
| 6 | Rate adaptive cardiac rhythm management device con… | 499 |
| 7 | Cardiac pacemaker with automatic response optimiza… | 496 |
| 8 | Vagal nerve stimulation techniques for treatment o… | 424 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
The combination of high concentration, a post-peak filing trajectory, and a narrow but real set of adjacent branches shapes where R&D resources can realistically generate differentiated IP.
Annual filings have eased back from the 2020 peak, and the lifecycle stage is classified as Decline. The foundational algorithmic space — core rate-response sensing and adaptation — is densely patented. R&D investment in this domain should target narrowly scoped improvements or interface with adjacent branches rather than broad algorithmic claims.
Lifecycle: DeclineWith the top five filers holding 64% of the hundred largest filers' combined total and Cardiac Pacemakers Inc alone holding 127 patent records, the core space is effectively oligopolistic. Challengers ranked sixth through tenth — including Intermedics Inc, ELA Medical SA, and Purdue Research Foundation — are separated from the leaders by a wide gap, reducing near-term competitive pressure on incumbents but also limiting collaboration leverage for smaller players.
High concentrationThe only co-applicant relationship evidenced in the data is between Jeffrey E. Stahmann and Cardiac Pacemakers Inc, with two co-filed records. The near-absence of collaborative filing suggests the field has historically been driven by proprietary, in-house development rather than open-innovation or university-industry partnerships — a structural gap that could be exploited by entrants willing to build cross-sector alliances, particularly in software and sensing branches.
Low collaborationThe United States is the lead filing jurisdiction by a wide margin, followed by the European Patent Office and WIPO PCT filings. Australia and Canada represent smaller but non-trivial secondary markets. Notably, China holds only one patent record in this corpus, indicating either limited enforcement interest in that market historically or a gap that could become strategically relevant as the Chinese medical-device sector develops.
US-centricGo beyond the landscape: Eureka's TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| Stahmann Jeffrey E | Cardiac Pacemakers Inc | 2 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
Two incumbent medical-device manufacturers hold commanding positions; a third, Biotronik, has recently entered with fresh activity, while Nevro Corp brings a distinctive digital-processing emphasis that differentiates it from the electrotherapy-focused mainstream.
The clear leader with 127 patent records, Cardiac Pacemakers Inc concentrates its portfolio in A61N 1 electrotherapy (112 records) with secondary positions in A61B 5 diagnosis and G01K 13 temperature measurement — a breadth that spans sensing inputs, stimulation delivery, and physiological monitoring. No recent momentum signal is available in the evidence for this applicant, consistent with an established, steady-state portfolio.
127 patent recordsRanked third with 28 patent records, Biotronik is flagged as a new entrant in the momentum data — meaning its recent filings represent a step-change relative to its prior activity. Its technology emphasis spans A61N 1 electrotherapy, A61B 5 diagnosis, and A61M 5 devices for body fluids, the last of which is uncommon among the top applicants and may indicate work on integrated drug-device or fluid-management interfaces alongside pacing.
28 patent records| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Biotronik SE & Co KG | 6 | ▲ new entrant |
Several IPC branches adjacent to the dominant A61N electrotherapy core carry low patent counts, making them worth watching as potential differentiation zones — though entry feasibility depends on specific technology capabilities and freedom-to-operate in the broader landscape.
With only 18 patent records and a 4% share among the top IPC branches, digital data processing applied to pacing algorithms is sparsely covered relative to the hardware-stimulation core. Nevro Corp has already established a foothold here with 15 records in G06F 19, suggesting the branch has real technical relevance for algorithm optimization, closed-loop control, and machine-learning-driven rate adaptation. An entrant with software expertise and access to clinical data could find a lower-density entry path here than in the core A61N space.
Search this in Eureka →Healthcare informatics holds 16 patent records at a 3% share, indicating that the integration of pacing algorithms with electronic health records, remote monitoring platforms, and decision-support systems remains thinly patented. As remote patient monitoring and cloud-connected cardiac devices become standard of care, this branch has plausible technical value. The sparse coverage and the absence of any dominant incumbent in this sub-space suggests a realistic entry path for organizations combining pacing expertise with health-IT capabilities.
Search this in Eureka →Cardiac Pacemakers Inc is the top-ranked filer with 127 patent records, followed by Medtronic Inc with 48 and Biotronik SE & Co KG with 28. These three incumbents together account for a substantial share of the top-ranked corpus.
The field is highly concentrated: the top five filers account for 64% of the hundred largest filers' combined total. The gap between the leader (127 records) and the second-ranked applicant (48 records) is wide, reinforcing the incumbents' structural advantage.
No. The lifecycle evidence classifies the field as Decline, with annual filings having eased back from a peak in 2020. The most recent years show very low counts, though some of that reflects normal publication lag rather than a complete cessation of activity.
The United States is the dominant jurisdiction, followed by the European Patent Office and WIPO PCT filings. Australia and Canada are smaller secondary markets. China holds only one patent record in this corpus, a notable gap given the size of the Chinese medical-device market.
Yes. G06F electric digital data processing (18 patent records, 4% share) and G16H healthcare informatics (16 patent records, 3% share) are the two most sparse adjacent branches. Both have plausible technical relevance for algorithm intelligence and remote monitoring, and neither is dominated by a single incumbent.
Collaboration is minimal. The only documented co-filing relationship in the evidence is between Jeffrey E. Stahmann and Cardiac Pacemakers Inc, covering two co-filed records. The field has been overwhelmingly driven by proprietary, in-house development, which may represent a structural gap for entrants seeking to build alliances.
This report's underlying patent dataset — filings, assignees, technology clusters — is open for developers via MCP and REST API. Free to start, 10,000 credits, no credit card required.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Help us improve
Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.
This page